Helicobacter pylori nanoparticles as a potential treatment of conventional multiple sclerosis.
Pezeshki
Mohammad Zakaria
MZ
Zarrintan
Sina
S
Zarrintan
Mohammad Hossein
MH
D004337:Drug Carriers / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000150:complications* / Q000276:immunology; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D018448:Models, Immunological; D009103:Multiple Sclerosis / Q000628:therapy*; D053758:Nanoparticles / Q000627:therapeutic use*
D004337:Drug Carriers